Investment Analysts’ Weekly Ratings Updates for Embecta (EMBC)

A number of research firms have changed their ratings and price targets for Embecta (NASDAQ: EMBC):

• 5/9/2026 – Embecta was downgraded by Wall Street Zen from “strong-buy” to “hold”.
• 5/8/2026 – Embecta was downgraded by Zacks Research from “hold” to “strong sell”.
• 5/6/2026 – Embecta was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 5/6/2026 – Embecta had its price target lowered by Mizuho from $12.00 to $5.00. They now have a “neutral” rating on the stock.
• 5/5/2026 – Embecta was downgraded by BTIG Research from “buy” to “neutral”.
• 4/13/2026 – Embecta had its price target lowered by Mizuho from $14.00 to $12.00. They now have a “neutral” rating on the stock.

Embecta Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Thursday, May 28th will be given a $0.01 dividend. The ex-dividend date is Thursday, May 28th. This represents a $0.04 annualized dividend and a yield of 1.3%. Embecta’s dividend payout ratio is 31.58%.

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.